Follicular Lymphoma

Case Review: Progression in Follicular Lymphoma

Carla Casulo, MD, discusses the challenges surrounding the treatment of patients with relapsed/refractory follicular lymphoma.

According to a single-institution retrospective study recently published in&nbsp;<em>Clinical Lymphoma, Myeloma &amp; Leukemia,&nbsp;</em>minimally toxic first-line therapies may be beneficial in early extranodal follicular lymphoma compared with observation.

New guidance has been developed for the management of adverse events observed with the use of copanlisib (Aliqopa) in patients with follicular lymphoma (FL) who are on third-line or later therapy.

Leo I. Gordon, MD,&nbsp;discusses recent updates in Hodgkin lymphoma and NHL and pointed to research on the horizon.

Carla Casulo, MD,&nbsp;discusses challenges in the management of patients with relapsed/refractory follicular lymphoma and progress being made toward predicting early relapse in these patients.

Carla Casulo, MD, discusses recent research for new frontline options for patients with newly diagnosed follicular lymphoma.

Sarah Rutherford, MD, discusses&nbsp;a pilot study at Weill Cornell Medicine investigating ribavirin as a treatment for patients with follicular lymphoma.

Ofatumumab was both active and well-tolerated at 2 different dose levels in treatment-na&iuml;ve patients with advanced follicular lymphoma who had low tumor burden, according to findings from a phase II, multicenter study recently published in the <em>British Journal of Haematology</em>.

In an interview with&nbsp;<em>Targeted Oncology&nbsp;</em>during the 2018 ASH Annual Meeting, Elizabeth Lihua Budde, MD, PhD, discussed the results seen from this trial for patients with FL and DLBCL. She shared plans for the next steps and how this treatment may impact the patient population.

In an interview with Targeted Oncology, Nathan H. Fowler, MD, discussed the current research for the treatment landscape of relapsed/refractory follicular lymphoma, including 3 clinical trials at MD Anderson that are currently accruing patients with this disease.

In an interview with&nbsp;<em>Targeted Oncology,&nbsp;</em>Stephen Douglas Smith, MD, discussed recent advancements in FL, new treatments currently being evaluated in clinical trials, and the challenges that still exist within this space.

Elizabeth Lihua Budde, MD, PhD, discusses how the phase I/Ib clinical trial for mosunetuzumab in patients with follicular lymphoma is different than other clinical trials.

Based on data from the phase III AUGMENT trial, a supplemental new drug application for the&nbsp;R²&nbsp;regimen of lenalidomide plus rituximab has been granted a priority review designation by the FDA&nbsp;as a therapy for patients with previously treated follicular lymphoma and marginal zone lymphoma.

Results of a multi-institutional, retrospective analysis showed that radiotherapy in localized follicular lymphoma resulted in 68.9% of patients having no disease progression at 5 years with fewer than 2% of patients experiencing an in-field relapse, according to a study published in <em>Blood</em>.

A new retrospective analysis of 640 newly diagnosed patients with follicular lymphoma found that patients who had achieved partial remission after 4 or more cycles of bendamustine plus rituximab experienced improved duration of response on maintenance rituximab compared with patients who received no maintenance treatment or who were in complete remission following induction with bendamustine plus rituximab.

According to an exploratory analysis of the GALLIUM trial, obinutuzumab-based chemotherapy resulted in fewer incidences of disease progression compared to rituximab-based chemotherapy in previously untreated patients with advanced follicular lymphoma.

Elizabeth L. Budde, MD, PhD, discusses the interim efficacy results form the phase I study of mosunetuzumab in patients with lymphomas.

John P. Leonard, MD, discusses the primary results from the randomized, double-blind phase III AUGMENT trial investigating the combination lenalidomide (Revlimid) plus rituximab (Rituxan) in patients with recurrent indolent lymphomas.

During a <em>Targeted Oncology</em> live case-based peer perspectives presentation, Jonathon B. Cohen, MD, MS, recently discussed the treatment considerations and decisions he makes when treating patients with classical Hodgkin Lymphoma